2015 American Transplant Congress
Explorative Analysis of ZEUS After 5 Years: Histological Assessment from Biopsy Analyses
1ZEUS Study Group, Germany; 2Novartis, Pharma, Germany; 3ZEUS Study Group, Switzerland.
Background: Analysis of pathologists' assessments and histological data allow for deeper insight on patient outcome together with investigator's final clinical diagnoses. Here we present 5…2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…2015 American Transplant Congress
Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart-Liver Transplantation
When transplanted simultaneously, the liver allograft has been thought to have an immunoprotective role on other organs. However, detailed studies on simultaneous heart-liver transplantation (SHLT)…2015 American Transplant Congress
Pancreas Transplantation Immunosuppression Induction With Rabbit Antithymocyte Globulin +/- Rituximab and Early Steroid Withdrawal: Experience With >500 Recipients
T-cell depleting antibody induction, often combined with steroid withdrawal, has become standard practice for pancreas transplantation. In this study, outcomes of >500 pancreas transplants using…2015 American Transplant Congress
Improved Long-Term Graft Survival in Renal Transplant Recipients With Donor Specific Antibodies (DSA) After Mycophenolic Acid Escalation
Background: DSA formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population indicate DSA formation is a…2015 American Transplant Congress
Incidence and Outcomes of Polyomavirus Infection in 639 Kidney Transplant Recipients: Are High Immunological Risk Characteristics More Relevant Than Specific Induction Or Maintenance Immunosuppressive Regimens?
Introduction. Polyomavirus-associated nephropathy (PVAN) is now recognized as an important cause of graft dysfunction and early kidney transplant loss. Over-immunosuppression is the main risk factor…2015 American Transplant Congress
Safety and Efficacy of Early Everolimus in De Novo Orthotopic Liver Transplantation
Purpose: To study the safety and efficacy of immunosuppression with Everolimus (EVL) within the first month after orthotopic liver transplantation.Patients and methods: Recipients who had…2015 American Transplant Congress
Non-Cytoreductive Immunosuppression Prevents Rejection of Vascularized Composite Allografts
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss such as an extremity or face. Immunosuppression-free donor-specific immunological tolerance has been successfully…2015 American Transplant Congress
A Randomized Cross-Over Phase 3b Study of the Pharmacokinetics of Once-Daily Extended Release MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus in African-Americans (ASERTAA)
The CYP3A5*1 genotype, highly prevalent in African Americans (AA), commonly necessitates higher tacrolimus (tac) dose requirements and may hinder efforts to obtain therapeutic drug levels.…2015 American Transplant Congress
First Dose Tacrolimus Level Is Better Than CYP3A5 Genotyping in Prediction of Target Tacrolimus Dose
Background: Tacrolimus dose highly varies among Asian kidney transplant recipients. This can be explained by variety of CYP3A5 expression. CYP3A5 genotyping is highly recommended for…
- « Previous Page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- …
- 138
- Next Page »